Glenmark shares jump after good Q4 2013 net profits

Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Shares in Glenmark Pharmaceuticals jumped by almost 2 per cent to Rs 528 after consolidated net profits of the company were better then expected for Q4 2013 results.

    The net profit of the company rose to 10.9 per cent to Rs 166.79 crore on 25.3 growth in revenue to Rs 1335.48 crore in Q4 March 2013 over Q4 March 2012.

    The Board of Directors recommend a final dividend of 200% i.e. Rs. 2 per equity share of the face value of Re. 1 each.

     

    Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with five molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries.

    GoodReturns.in

    Read more about: glenmark
    Story first published: Wednesday, May 8, 2013, 10:35 [IST]
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more